Sunitinib - Wikipedia
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma | BMC Cancer | Full Text
Kaplan-Meier curves showing PFS in patients with sunitinib adverse... | Download Scientific Diagram
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - ScienceDirect
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Diagnostics | Free Full-Text | Clear Cell Renal Cell Carcinoma Spinal Metastases: Which Factors Matter to the Overall Survival? A 10-Year Experience of a High-Volume Tumor Spine Center
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
322-Renal cell metastatic sUNITinib | eviQ
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Kaplan-Meier analysis of overall survival by first targeted therapy | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis - Annals of Oncology
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib | British Journal of Cancer
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma | British Journal of Cancer
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. | Semantic Scholar
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma | Scientific Reports
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
